The impact of rare and low-frequency genetic variants in common disease.
Bomba L, Walter K, Soranzo N. · 2017
Read The impact of rare and low-frequency genetic variants in common disease. by Bomba L, Walter K, Soranzo N. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5408830.txt.
Introduction
Lorenzo Bomba, Klaudia Walter, and Nicole Soranzo review rare genetic variants and common disease in a 2017 Genome Biology paper. Large scans have found thousands of gene spots tied to common diseases and traits, yet much of the inherited risk stays unexplained. Common variants were the easy finds. Cheaper full gene reading now lets teams hunt the rare and low-frequency variants that older scans missed.
The review covers how such hunts are designed, what they have found so far, and where the hard parts lie. Rare variants can have larger effects and can point straight at the gene at fault, which aids drug design. But they demand huge samples and care in reading the data. The authors weigh what these finds could mean for care tailored to each patient's genes.
Catalog record
| CREATOR | Bomba L, Walter K, Soranzo N. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 85 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The impact of rare and low-frequency genetic variants in common disease By Lorenzo Bomba, Klaudia Walter, Nicole Soranzo Published in: Genome Biology DOI: 10.1186/s13059-017-1212-4 ABSTRACT Despite thousands of genetic loci identified to date, a large proportion of genetic variation predisposing to complex disease and traits remains unaccounted for. Advances in sequencing technology enable focused explorations on the contribution of low-frequency and rare variants to human traits. Here we review experimental approaches and current knowledge on the contribution of these genetic variants in complex disease and discuss challenges and opportunities for personalised medicine. Electronic supplementary material The online version of this article (doi:10.1186/s13059-017-1212-4) contains supplementary material, which is available to authorized users. INTRODUCTION Genetic research has played an instrumental role in the discovery of new biological pathways underpinning complex human disease and the evaluation of new targets for therapeutic development. The past decade has seen an exponential increase in the number of known genetic loci predisposing to complex disease, enabled by large-scale meta-analyses based on genome-wide single-nucleotide polymorphism (SNP) arrays imputed into reference haplotype panels [1]. These efforts have identified thousands of (mostly common) genetic loci associated with disease biomarkers and disease endpoints [2], with some initial examples of how these genetic findings can be used to inform disease prediction [3], identification of causal mechanisms of disease [4, 5] and the prioritisation of new biological targets in drug discovery programmes [6–8]. Many challenges continue to exist in both the discovery and interpretation of findings from genome-wide association studies (GWASs). Highly successful international collaborative efforts have enabled association studies to reach unprecedented sizes of thousands to hundreds of thousands of study participants [9–12]. Despite the increases in statistical power afforded by these large-scale studies, for the majority of human traits genetic associations discovered account for a fraction of disease or trait heritability (the “missing heritability” paradigm). Genetic variants that are outside the reach of the most statistically powered association studies [13] are thought to contribute to the missing heritability of many human traits, including common variants (here denoted by minor allele frequency [MAF] >5%) of very weak effect, low-frequency (MAF 1–5%) and rare variants (MAF <1%) of small to modest effect, or a combination of both, with several possible scenarios all deemed plausible in simulation studies [14]. Empirical studies attempting to understand the impact of rare or less common variation on human complex diseases and traits remain to date relatively limited [15, 16], but some lessons on their properties are beginning to emerge from exome-wide and genome-wide sequencing studies. For most traits, these studies have demonstrated an inverse relationship between the variant’s “regression effect size” (or disease odds ratio) and its frequency in the population, as predicted by population genetic models [17]. Differential selective pressures acting on variants across the allele frequency spectrum underpin the observed shape of this relationship in different human traits. Such a relationship tends to be skewed in favour of rare variants for traits most strongly influenced by natural selection, compared with quantitative phenotypes or late-onset diseases [17]. Mendelian diseases are at the extreme end of the spectrum because of the high impact of selection on transmission of rare variants to subsequent generations. Initial evidence for complex diseases suggests that autism spectrum disorders may be skewed towards rarer susceptibility variants [18] compared with diseases such as type 2 diabetes [19], age-related macular degeneration [15] and schizophrenia [20], and quantitative cardiometabolic traits [21, 22]. Further efforts to discover associations driven by low-frequency and rare variants through genome sequencing and large-scale imputation efforts allow continuous refinements of the proportion of trait heritability explained by variants across the frequency spectrum [23]. Finally, it is worth noting that estimates of missing heritability from genome-wide variants are strongly dependent on assumptions on linkage disequilibrium, allele frequency and genotype certainty [13, 24]. Rare SNPs have been estimated to contribute substantial fractions of heritability (half the heritability of common SNPs [25]), but these early estimates will likely be revised as data continue to be accrued. Another important challenge for complex disease genetics is the identification and functional characterisation of causal variants, or mutations in relevant genes, responsible for association signals detected through GWASs [26]. Common risk variants map overwhelmingly to regulatory regions [12], where inference of the underlying causative genes is difficult. Recent developments in cellular and functional genomics provide effective strategies to annotate the clinical and phenotypic consequences of genome sequence variation [27]. These approaches, which investigate a range of processes such as transcription, translation and epigenetic regulation at the organismal, physiological or cellular level [28], are a necessary step towards our understanding of the complex relationship between genotype and phenotype on a global (genome-wide) scale. Even in the presence of expansive datasets for annotation, however, the interpretation of the precise functional consequence of each variant requires rigorous and often painstaking evaluation of many genes in different possible cellular and environmental contexts [29]. On the other hand, rare variants in or near gene targets display larger average effects on phenotype compared with both regulatory variants of comparable allele frequencies and common genetic variants [21, 30]. The discovery of these variants through focused sequencing explorations of protein-coding regions is expected to greatly facilitate the task of annotating genes underpinning genetic associations with complex disease and describing the functional consequences of human sequence variation. There are, therefore, compelling arguments to accelerate efforts to identify variants within these regions because of the relative ease with which these discoveries can be turned into biological insights. Here we review the current state of knowledge from rare variant association studies (RVASs) of complex traits and review approaches for discovering and testing associations for rare variants. Further, we discuss the growing body of literature documenting examples of highly clinically informative genetic variants identified through bespoke genotyping arrays, imputation and population-scale whole-exome and whole-genome sequencing. GENOMIC TOOLS FOR ASSESSING LOW-FREQUENCY AND RARE VARIANTS Three broad strategies are available to access low-frequency and rare variants: genotype imputation, the use of custom genotyping arrays and the use of whole-exome or whole-genome sequencing. Imputation Genotype imputation provides a cost-effective strategy for expanding the SNP content of genome-wide genotyping arrays. It relies on the availability of reference panels of phased haplotypes that can be used to impute genotypes into sparse datasets generated by commercial genotyping arrays [31, 32]. Multiple different reference panels have been generated since 2005, enabled by expanding collections of polymorphisms in human populations. The first two widely used reference panels generated by the HapMap project included 269 samples and just over one million SNPs (phase I) [33] and 3.1 million SNPs (phase II) [34], respectively. The ascertainment of these early panels was strongly skewed towards common variants (MAF >5%) found near human genes, thus limiting the representation of low-frequency and rare variants in early GWASs [35]. HapMap phase III included 1.6 million SNPs in 1184 individuals from 11 populations, ascertained by common SNP repositories and from targeted resequencing of ten 100-kb regions in 692 of these individuals. Compared with previous reference panels, the authors demonstrated gains in imputation accuracy particularly for low-frequency and rare variants [36]. Further improvements in imputation panels were enabled by large-scale whole-genome sequencing (WGS) efforts in reference human populations, and particularly the 1000 Genomes Project (pilot, phase I and